KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer: 5-year extended follow-up for the randomized phase III KEYNOTE-590 study.

J-P Metges, K Kato, J-M Sun, L Shen, P C Enzinger, A Adenis, T Doi, T Kojima, Z Li, S-B Kim, B C Cho, W Mansoor, S-H Li, P Sunpaweravong, M Alsina, G L Buchschacher, H Hara, A Tsuji, J Wu, S Shah, P Bhagia, M A Shah

ESMO Open 10(12) 105854

PMID41259897
PMCIDPMC12670541
DOI10.1016/j.esmoop.2025.105854
发表日期2025-11-19
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

BACKGROUND: The global KEYNOTE-590 trial was the first to show a significant improvement in survival with immunotherapy plus chemotherapy in the first-line treatment of esophageal cancer (EC) and supported the approval of pembrolizumab plus chemotherapy in this setting. After a median follow-up of 22.6 months, pembrolizumab plus chemotherapy compared with placebo plus chemotherapy had a manageable safety profile and significantly improved survival of participants with previously untreated advanced EC. Results of a median follow-up of 58.8 months (range 49.2-70.6 months) are reported. PATIENTS AND METHODS: Adults with previously untreated advanced EC or Siewert type 1 gastroesophageal junction cancer were randomly assigned 1 : 1 to receive chemotherapy with or without pembrolizumab. Study outcomes were efficacy and safety. RESULTS: Overall, 749 participants received pembrolizumab plus chemotherapy (n = 373) or placebo plus chemotherapy (n = 376). Median overall survival was 12.3 months versus 9.8 months [hazard ratio (HR) 0.72, 95% confidence interval (CI) 0.62-0.84] with pembrolizumab plus chemotherapy versus placebo plus chemotherapy; 5-year survival rates were 10.6% and 3.0%. Median progression-free survival (PFS) was 6.3 months versus 5.8 months (HR 0.64, 95% CI 0.54-0.75); 5-year PFS rates were 5.5% and not reached. Grade ≥3 treatment-related adverse events occurred in 71.9% and 67.6% of participants in the pembrolizumab plus chemotherapy and placebo plus chemotherapy groups, respectively. CONCLUSION: Data from KEYNOTE-590 continue to show durable efficacy after 5 years, and pembrolizumab plus chemotherapy more than tripled the 5-year overall survival rate compared with placebo plus chemotherapy, with no new safety signals. These results support first-line therapy with pembrolizumab plus chemotherapy as standard for previously untreated patients with advanced EC with programmed death-ligand 1 combined positive score ≥1.

KM 提取结果

1 个 Figure · 3 个 KM 面板

进入结果中心
KM Figure3 个面板

Figure 2

Figure 2 Efficacy outcomes. (A-E) Kaplan–Meier estimates of overall survival in (A) all randomly assigned participants in the intention-to-treat population, (B) participants with PD-L1 CPS ≥1, (C) participants with PD-L1 CPS ≥10, (D) participants with ESCC, and (E) participants with ESCC PD-L1 CPS ≥10. (F-I) Kaplan–Meier estimates of progression-free survival in (F) all randomly assigned participants in the intention-to-treat population, (G) participants with PD-L1 CPS ≥1, (H) participants with PD-L1 CPS ≥10, and (I) participants with ESCC. The intention-to-treat population included all randomly assigned participants. CI, confidence interval; CPS, combined positive score; ESCC, esophageal squamous-cell carcinoma; HR, hazard ratio; OS, overall survival; PD-L1, programmed death-ligand 1; PFS, progression-free survival.

G

progression-free survival

Figure 2 · Panel G

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel G 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
H

progression-free survival

Figure 2 · Panel H

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel H 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
I

progression-free survival

Figure 2 · Panel I

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel I 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1 CONSORT diagram.
非 KM Figure